Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation
US11819498B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2020 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | Mar 27, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.